Home
>
US Stocks
>
Canopy Growth Corporation

Canopy Growth Corporation (CGC)

$0.8751

[object Object]

(-0.25%)▲

Live

Insights on Canopy Growth Corporation

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 117.86M → 113.34K (in $), with an average decrease of 99.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -2.08B → -261.58K (in $), with an average increase of 42766.5% per quarter

  • Vs NBIX

    In the last 1 year, Canopy Growth Corporation has experienced a drawdown of -82.0%, however Neurocrine Biosciences, Inc. resisted the overall trend and outperformed by 80.0%

  • Vs ZTS

    In the last 3 years, Canopy Growth Corporation has experienced a drawdown of -94.9%, however Zoetis Inc - Class A resisted the overall trend and outperformed by 68.0%

Performance

  • $0.87
    $0.89
    $0.88
    downward going graph

    0.94%

    Downside

    Day's Volatility :2.1%

    Upside

    1.17%

    downward going graph
  • $0.87
    $5.18
    $0.88
    downward going graph

    1.03%

    Downside

    52 Weeks Volatility :83.19%

    Upside

    83.01%

    downward going graph

Returns

PeriodCanopy Growth CorporationSector (Health Care)Index (Russel 2000)
3 Months
-61.86%
0.3%
-6.7%
6 Months
-75.77%
-8.3%
-6.2%
1 Year
-82.35%
-4.8%
-6.3%
3 Years
-94.68%
23.8%
26.9%

Highlights

Market Capitalization
458.2M
Book Value
$2.88
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-4.41
Wall Street Target Price
1.51
Profit Margin
0.0%
Operating Margin TTM
-114.96%
Return On Assets TTM
-6.79%
Return On Equity TTM
-112.0%
Revenue TTM
441.0M
Revenue Per Share TTM
1.01
Quarterly Revenue Growth YOY
-28.199999999999996%
Gross Profit TTM
-81.9M
EBITDA
-412.7M
Diluted Eps TTM
-4.41
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.48
EPS Estimate Next Year
-0.53
EPS Estimate Current Quarter
-0.17
EPS Estimate Next Quarter
-0.16

Analyst Recommendation

Sell
    4%Buy
    40%Hold
    54%Sell
Based on 22 Wall street analysts offering stock ratings for Canopy Growth Corporation(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
9
9
9
Sell
12
13
13

Analyst Forecast

What analysts predicted

Upside of 72.55%

Current $0.88
Target $1.51

Company Financials

FY17Y/Y Change
Revenue
39.9M
↑ 214.16%
Net Income
-16.6M
↑ 375.03%
Net Profit Margin
-41.63%
↓ 14.1%
FY18Y/Y Change
Revenue
77.9M
↑ 95.38%
Net Income
-70.4M
↑ 323.63%
Net Profit Margin
-90.26%
↓ 48.63%
FY19Y/Y Change
Revenue
226.3M
↑ 190.37%
Net Income
-685.4M
↑ 874.28%
Net Profit Margin
-302.83%
↓ 212.57%
FY20Y/Y Change
Revenue
398.8M
↑ 76.18%
Net Income
-1.3B
↑ 92.77%
Net Profit Margin
-331.35%
↓ 28.52%
FY21Y/Y Change
Revenue
546.6M
↑ 37.08%
Net Income
-1.7B
↑ 32.06%
Net Profit Margin
-319.2%
↑ 12.15%
FY22Y/Y Change
Revenue
416.9M
↓ 4.82%
Net Income
-242.1M
↓ 82.68%
Net Profit Margin
-58.08%
↑ 261.12%
Q3 FY21Q/Q Change
Revenue
103.6M
↓ 3.55%
Net Income
-8.7M
↓ 102.82%
Net Profit Margin
-8.42%
↓ 296.52%
Q4 FY21Q/Q Change
Revenue
110.6M
↑ 7.31%
Net Income
-85.5M
↑ 885.03%
Net Profit Margin
-77.27%
↓ 68.85%
Q1 FY22Q/Q Change
Revenue
89.5M
↓ 20.71%
Net Income
-460.4M
↑ 427.53%
Net Profit Margin
-514.11%
↓ 436.84%
Q2 FY22Q/Q Change
Revenue
85.5M
↓ 1.48%
Net Income
-1.6B
↑ 262.53%
Net Profit Margin
-1.9K%
↓ 1377.68%
Q3 FY22Q/Q Change
Revenue
86.2M
↑ 7.04%
Net Income
-162.2M
↓ 89.35%
Net Profit Margin
-188.19%
↑ 1703.6%
Q4 FY22Q/Q Change
Revenue
83.7K
↓ 99.9%
Net Income
-193.2K
↓ 99.88%
Net Profit Margin
-230.78%
↓ 42.59%
FY17Y/Y Change
Total Assets
677.6M
↑ 372.66%
Total Liabilities
62.9M
↑ 221.15%
FY18Y/Y Change
Total Assets
1.4B
↑ 112.04%
Total Liabilities
193.6M
↑ 207.91%
FY19Y/Y Change
Total Assets
8.7B
↑ 507.72%
Total Liabilities
1.5B
↑ 669.9%
FY20Y/Y Change
Total Assets
6.9B
↓ 21.46%
Total Liabilities
1.7B
↑ 12.72%
FY21Y/Y Change
Total Assets
6.8B
↓ 0.5%
Total Liabilities
3.2B
↑ 90.59%
FY22Y/Y Change
Total Assets
4.5B
↓ 17.71%
Total Liabilities
1.6B
↓ 38.01%
Q3 FY21Q/Q Change
Total Assets
5.1B
↓ 6.83%
Total Liabilities
1.7B
↓ 22.89%
Q4 FY21Q/Q Change
Total Assets
5.0B
↓ 2.8%
Total Liabilities
1.6B
↓ 3.6%
Q1 FY22Q/Q Change
Total Assets
4.5B
↓ 11.0%
Total Liabilities
1.6B
↓ 5.38%
Q2 FY22Q/Q Change
Total Assets
2.7B
↓ 37.36%
Total Liabilities
1.4B
↓ 7.56%
Q3 FY22Q/Q Change
Total Assets
2.5B
↓ 3.28%
Total Liabilities
1.3B
↓ 5.25%
Q4 FY22Q/Q Change
Total Assets
2.2M
↓ 99.91%
Total Liabilities
1.2M
↓ 99.91%
FY17Y/Y Change
Operating Cash Flow
-27.1M
↑ 117.68%
Investing Cash Flow
-18.6M
↑ 63.49%
Financing Cash Flow
132.1M
↑ 606.41%
FY18Y/Y Change
Operating Cash Flow
-81.5M
↑ 200.84%
Investing Cash Flow
-223.6M
↑ 1101.93%
Financing Cash Flow
525.8M
↑ 298.07%
FY19Y/Y Change
Operating Cash Flow
-520.5M
↑ 538.62%
Investing Cash Flow
-3.2B
↑ 1343.75%
Financing Cash Flow
5.8B
↑ 1010.05%
FY20Y/Y Change
Operating Cash Flow
-772.6M
↑ 48.44%
Investing Cash Flow
-347.7M
↓ 89.23%
Financing Cash Flow
-57.2M
↓ 100.98%
FY21Y/Y Change
Operating Cash Flow
-465.7M
↓ 39.72%
Investing Cash Flow
-884.1M
↑ 154.31%
Financing Cash Flow
1.3B
↓ 2312.64%
FY22Y/Y Change
Operating Cash Flow
-437.3M
↑ 17.19%
Investing Cash Flow
184.9M
↓ 126.11%
Financing Cash Flow
-36.5M
↓ 103.6%
Q3 FY21Q/Q Change
Operating Cash Flow
-67.8M
↓ 48.15%
Investing Cash Flow
258.8M
↓ 187.64%
Financing Cash Flow
-1.4M
↓ 96.19%
Q4 FY21Q/Q Change
Operating Cash Flow
-131.3M
↑ 94.71%
Investing Cash Flow
-19.5M
↓ 107.56%
Financing Cash Flow
269.1K
↓ 120.02%
Q1 FY22Q/Q Change
Operating Cash Flow
-101.5M
↓ 24.31%
Investing Cash Flow
241.9M
↓ 1317.18%
Financing Cash Flow
644.9K
↑ 134.69%
Q2 FY22Q/Q Change
Operating Cash Flow
-109.1M
↑ 10.92%
Investing Cash Flow
188.5M
↓ 19.57%
Financing Cash Flow
-810.4K
↓ 229.69%
Q3 FY22Q/Q Change
Operating Cash Flow
-97.6M
↓ 5.06%
Investing Cash Flow
62.6M
↓ 64.76%
Financing Cash Flow
-8.3M
↑ 988.98%

Technicals Summary

Sell

Neutral

Buy

Canopy Growth Corporation is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Canopy Growth Corporation
Canopy Growth Corporation
-31.99%
-75.77%
-82.35%
-94.68%
-96.96%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-12.31%
-28.21%
-2.43%
-26.08%
-4.62%
Zoetis Inc.
Zoetis Inc.
-8.25%
6.88%
-3.62%
19.08%
95.07%
Viatris Inc.
Viatris Inc.
-2.67%
-17.41%
-25.75%
-44.25%
-44.25%
Catalent, Inc.
Catalent, Inc.
-25.94%
-25.95%
-63.98%
-51.57%
-7.2%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Canopy Growth Corporation
Canopy Growth Corporation
NA
NA
NA
-4.48
-1.12
-0.07
0.0
2.88
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
147.13
147.13
1.87
1.93
0.04
0.08
0.0
17.28
Zoetis Inc.
Zoetis Inc.
37.27
37.27
3.53
5.4
0.45
0.13
0.01
9.72
Viatris Inc.
Viatris Inc.
5.8
5.8
NA
2.95
0.09
0.03
0.05
17.45
Catalent, Inc.
Catalent, Inc.
16.21
16.21
1.18
1.37
0.09
0.04
0.0
27.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Canopy Growth Corporation
Canopy Growth Corporation
Sell
$458.2M
-96.96%
NA
0.0%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$8.9B
-4.62%
147.13
4.0%
Zoetis Inc.
Zoetis Inc.
Buy
$76.1B
95.07%
37.27
25.59%
Viatris Inc.
Viatris Inc.
Hold
$10.9B
-44.25%
5.8
12.05%
Catalent, Inc.
Catalent, Inc.
Buy
$6.7B
-7.2%
16.21
8.62%

Institutional Holdings

  • Vanguard Group Inc

    2.00%

  • Millennium Management LLC

    1.64%

  • Mirae Asset Global Investments (Korea) Co Ltd

    0.56%

  • Susquehanna International Group, LLP

    0.52%

  • Morgan Stanley - Brokerage Accounts

    0.41%

  • Ameriprise Financial Inc

    0.24%

Corporate Announcements

  • Canopy Growth Corporation Earnings

    Canopy Growth Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

Canopy Growth is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation,the Company offers product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Its global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through its award-winning Tweed and Tokyo Smoke banners, the Company reach its adult-use consumers and hasbuilt a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States, and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through its First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands.

Organization
Canopy Growth Corporation
Employees
3151
CEO
Mr. David Eric Klein
Industry
Process Industries

Discover More

FAQs